New gel shows promise for diabetic wound healing
NCT ID NCT06608303
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a gel containing a protein called GM-CSF on 40 people with diabetic wounds that were in the healing (granulation) phase. The gel aims to boost the body's own repair cells to help wounds close faster. Researchers measured how much the wound size shrank and checked for side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- human granulocyte macrophage stimulating factor gel (JinFuNing)
- What this could lead to
- If it works, this gel could speed up healing of diabetic wounds, reducing infection risk and improving quality of life.
- What could go wrong
- This is a small, completed study with only 40 participants. The results may not apply to all diabetic wounds, and the gel may not work better than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
40 people
The number who actually took part.
- Started
-
Oct 2024
- Finished
-
Oct 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * a confirmed diagnosis of type 1 or type 2 diabetes mellitus that meets the standard World Health Organization definition, with blood glucose controlled prior to enrolment and a glycated haemoglobin HbA1c level of less than 10%; * the type of wound is an ulcer; * the wound etiology is diabetic, mainly abnormalities in blood glucose, resulting in poor or prolonged healing and requiring standard wound therapy; * the staging of the wound is in the granulation phase; * voluntary participation in the study and signing of an informed consent form. Exclusion Criteria: * acute heart attack, heart failure, hepatitis, shock, expiratory failure and other serious diseases that have not been corrected; * uncontrolled blood glucose, fasting blood glucose \> 15 mmol/L and glycated haemoglobin \> 12%; * active bleeding in the wound, which does not allow the implementation of the conventional basic treatment plan; * serum albumin \< 20 g/L; haemoglobin \< 60 g/L; platelets \< 50 x 109/L; * a state of disseminated infection that is being or will be treated with antibiotics * patients with advanced malignant tumours; * active autoimmune disease; * previous allergy to topical human granulocyte macrophage stimulating factor gel (Jinfuning); * inability of the patient to co-operate or mental disorder; * in the judgement of the investigator, the subject has a clearly irremovable cause of wound healing, is unsuitable for the study or is unable to comply with the requirements of the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetic wound are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100191, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.